We conducted a double-blind, placebo-controlled, dose-ranging phase 2b trial to evaluate the safety and efficacy of zodasiran in adults with mixed hyperlipidemia (fasting triglyceride level of 150 ...

Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;Epub ahead of print. Ballantyne CM, Vasas S, Aziad M, et al.

Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non–high-density lipoprotein (HDL) cholesterol level, which is driven by remnant ...

Mixed hyperlipidemia was defined as triglycerides 150 mg/dL to 499 mg/dL and LDL at least 70 mg/dL or non-HDL at least 100 mg/dL. Patients had been taking statins for at least 4 weeks or were ...

What is mixed hyperlipidemia? When you have this, you have high triglycerides and LDL, as well as low HDL. It's an inherited condition, part of a group called "familial hyperlipidemia." ...

Arrowhead Pharmaceuticals, Inc. today announced results from the Phase 2 b double blind, randomized MUIR study of investigational plozasiran in patients with mixed hyperlipidemia. These data were ...

Mixed hyperlipidemia can be passed down through families, which is why it's also called familial combined hyperlipidemia. People with mixed hyperlipidemia may develop high cholesterol or high ...

Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia – elevations of triglycerides and cholesterol ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed ...

Mixed hyperlipidemia, also called mixed dyslipidemia, is a highly prevalent disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride levels.

PASADENA, Calif., May 28, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...